Perrigo

Perrigo Co. Plc engages in the provision of self-care products and over-the-counter (OTC) health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the following segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The CSCI segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Perrigo reports strong Q1 growth, faces challenges in product shortages

Perrigo's Q1 2023 performance showcased growth and margin expansion, with a focus on operational excellence. The company faces challenges with product shortages and declining national brand volumes but sees opportunities in pricing increases and supply chain optimization. By leveraging strengths in private label growth and strategic initiatives, Perrigo aims to deliver on guidance for the year.

Perrigo reports strong Q2 performance, eyes Opill launch success

Perrigo's Q2 2023 earnings call highlighted strong financial performance, strategic strengths, key challenges, and growth opportunities. The company is focused on sustainable growth, market differentiation, and leveraging its capabilities for success in the industry.

Perrigo reports solid Q3 earnings, navigates challenges for future growth

Perrigo's Q3 performance showcased growth in net sales and margin expansion, despite challenges in certain product segments. The company remains focused on margin improvement, supply chain optimization, and growth initiatives for future success. With revised outlooks and ongoing strategic efforts, Perrigo aims to navigate challenges and capitalize on growth opportunities.

Perrigo reports robust Q4 earnings, focuses on growth initiatives

Perrigo's Q4 2023 earnings call showcased strong financial performance, with notable growth in net sales and margins.
While facing challenges in its infant formula business, the company outlined remediation plans and expects recovery in the second half of 2024.
Opportunities lie in the launch of Opill, Project Energise, and a focus on strengthening the infant formula business.
Perrigo aims to drive growth by executing strategic initiatives and providing more clarity on growth perspectives during an upcoming Investor Day.

Perrigo reports Q1 challenges, Opill success, and growth opportunities

Perrigo faced challenges in net sales due to infant formula actions but showed strength in innovation and store brands.
Opportunities lie in adapting to retailer inventory changes and expected gross margin improvement in Q2.
The company remains on track to meet 2024 commitments with progress in infant formula recovery and successful product launches.
Analysts focused on infant formula progress, Opill revenue potential, and portfolio refinements during the call.

Perrigo reports Q2 resilience amidst challenges, eyes growth opportunities

Perrigo faced challenges in Q2 2024 with a decline in organic net sales, primarily due to infant formula and certain category sales. Despite this, the company showed resilience with growth in operating income and a focus on core segments. Opportunities lie in recovering share, enhancing marketing, and the potential for infant formula recovery.

Perrigo reports robust Q3 earnings, focuses on efficiency and growth

Perrigo's Q3 performance reflects a resilient financial position, marked by strong EPS growth and operational efficiency gains through cost-saving initiatives.
While facing challenges in net sales decline, the company's strategic focus on core business stabilization and efficiency improvements bodes well for long-term growth.
With a commitment to financial targets, Perrigo is poised to capitalize on opportunities for revenue diversification and market expansion, supported by a strengthened operational foundation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Perrigo Co. Plc engages in the provision of self-care products and over the counter health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the Consumer Self-Care Americas and Consumer Self-Care International segments. The Consumer Self-Care Americas segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The Consumer Self-Care International segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Perrigo Company Plc (NYSE:PRGO ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Murray Kessler - President, Chief Executive Officer Eduardo Bezerra - Executive Vice President, Chief Financial Officer Brad Joseph - Vice President, Investor Relations Conference Call Participants Chris Neamonitis - Jefferies Elliot Wilbur - Raymond James Chris Schott - JP Morgan Operator Good morning and welcome to the Perrigo second quarter 2022 financial results conference call. All participants will be in listen-only mode.

Perrigo (PRGO) CEO, Murray Kessler on Q2 2022 Results - Earnings Call Transcript

Perrigo (PRGO) delivered earnings and revenue surprises of -2.27% and 5.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) Lags Q2 Earnings Estimates

DUBLIN , Aug. 9, 2022 /PRNewswire/ -- Second Quarter 2022 Highlights: Perrigo achieved second quarter net sales of $1.1 billion, an increase of 14.3%, or 20.2% excluding the impact of currency translation, versus the prior year quarter. Organic(1) net sales increased 17.2%, driven by continued strong global demand for the Company's consumer self-care products.

PERRIGO REPORTS SECOND QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONS

DUBLIN , July 27, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it will release its second quarter 2022 financial results on Tuesday, August 9, 2022. The Company will also host a conference call beginning at 8:30 A.M.

PERRIGO TO RELEASE SECOND QUARTER 2022 FINANCIAL RESULTS ON AUGUST 9, 2022

The acquisition of HRA Pharma to drive significant revenue and earnings growth for Perrigo in the coming quarters. PRGO is facing contracted gross margins due to inflationary headwinds.

Perrigo: HRA Acquisition To Drive Significant Growth

The FDA's potential approval of Perrigo (PRGO) unit, HRA Pharma's OTC birth control pills can make the drug the first of its kind to be made available without prescription in the United States.

Perrigo (PRGO) Unit Files for OTC Birth Control Pill With FDA

A company is asking the FDA to make its progestin-only pill available without prescription.

FDA Might Authorize First Over-the-Counter Birth Control Pill

The application from the Paris-based HRA Pharma comes on the back of the U.S. Supreme Court's decision in June to overturn the 1973 Roe v. Wade case that legalized abortion nationwide

FDA to review first ever over-the-counter birth control pill

HRA executives expect a decision by the FDA in the first half of 2023

FDA to consider pharma company's application for over-the-counter birth control pill

Perrigo Company said on Monday its unit has submitted an application to the U.S. Food and Drug Administration (FDA) for approval of an over-the-counter (OTC) birth control pill.

Perrigo unit submits approval application to FDA for OTC birth control pill

DUBLIN and ALLEGAN, Mich. , July 11, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that HRA Pharma, a Perrigo company, has submitted its application to the United States Food and Drug Administration (FDA) for the first-ever over-the-counter (OTC) birth control pill in the United States.

Perrigo's HRA Pharma Submits Application to FDA for First-Ever OTC Birth Control Pill

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?

Why Is Perrigo (PRGO) Up 13.4% Since Last Earnings Report?

Self-care health and wellness products make Perrigo (NASDAQ: PRGO) stock has been recovering well off its $31.22 bottom.

Perrigo Stock is a Second Half Expansion Play

DUBLIN , June 1, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) today announced that Ms. Alison Ives has been promoted to Executive Vice President and Chief Scientific Officer.

PERRIGO PROMOTES ALISON IVES TO ROLE OF CHIEF SCIENTIFIC OFFICER

DUBLIN , May 26, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it has received final approval from the U.S. Food and Drug Administration for Omeprazole Magnesium Delayed-Release Mini Capsules, 20 mg over-the-counter (OTC). Perrigo expects to launch Omeprazole Minis later this year.

PERRIGO ANNOUNCES U.S. FDA APPROVAL FOR OMEPRAZOLE MAGNESIUM DELAYED-RELEASE MINI CAPSULES

DUBLIN , May 19, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO, Murray S. Kessler and CFO Eduardo Bezerra are scheduled to participate in investor meetings at the Credit Suisse HALO Investment Summit held in New York City on Wednesday, May 25 th.

PERRIGO TO PRESENT AT UPCOMING CONSUMER INVESTOR CONFERENCES

Perrigo Company PLC, which makes store-brand baby formulas for retailers including Walmart Inc and Amazon.com Inc expects shortages and heightened demand to last for the "balance of the year," said CEO Murray Kessler in an interview with Reuters.

Exclusive-Maker of Walmart, Amazon store-brand infant formulas expects shortages through rest of 2022

Perrigo Company plc (NYSE:PRGO ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Bradley Joseph - Vice President of Investor Relations Murray Kessler - President and Chief Executive Officer Raymond Silcock - Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Elliot Wilbur - Raymond James Operator Good day and welcome to the Perrigo First Quarter 2022 Financial Results Conference Call. All participants will be in a listen-only mode.

Perrigo Company plc (PRGO) CEO Murray Kessler on Q1 2022 Results - Earnings Call Transcript

Perrigo Company plc's (NYSE: PRGO) Q1 FY22 sales increased 6.4% Y/Y to $1.07 billion, almost in line with the consensus of $1.1 billion. The growth was led by strong consumer demand, particularly for cough/cold products globally and infant formula in the U.S. after.

Perrigo Shares Pop On Raised FY22 Guidance Surpassing Consensus Estimates

Perrigo (PRGO) reports mixed first-quarter 2022 results. Sales of cough/cold products continue the strong rebound during the reported quarter.

Perrigo (PRGO) Q1 Earnings Miss, Margins Hurt by Higher Costs

Perrigo (PRGO) delivered earnings and revenue surprises of -21.43% and 1.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) Q1 Earnings Lag Estimates

Perrigo PLC shares PRGO, +0.37% slid 4% in premarket trade Wednesday, after the personal self-care product maker swung to a loss for the first quarter and fell short of estimates. The Dublin-based Perrigo posted a net loss of $2.4 million, or 2 cents a share, after income of $38.1 million, or 28 cents a share, in the year-earlier period.

Perrigo shares slide 4% premarket after company swings to Q1 loss

DUBLIN, May 11, 2022 /PRNewswire/ -- Highlights: Perrigo achieved first quarter net sales of $1.1 billion, an increase of 6.4% versus the prior year quarter. Organic(1) net sales increased 9.7%, led by continued strong consumer demand, particularly for cough/cold products globally and infant formula in the U.S. Reported loss per diluted share for the first quarter of 2022 was $0.01, as compared to earnings per diluted share ("EPS") of $0.02 in the prior year quarter.

PERRIGO REPORTS FIRST QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONS, RAISES GUIDANCE

Mr. Eduardo G. Bezerra named EVP, Chief Financial Officer Mr.

PERRIGO ANNOUNCES PLANNED LEADERSHIP SUCCESSION

Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Perrigo Stock (PRGO)